These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31603042)

  • 1. Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Damasceno A; Pimentel-Silva LR; Damasceno BP; Cendes F
    Mult Scler; 2020 Nov; 26(13):1740-1751. PubMed ID: 31603042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between cognitive and clinical disability across MS subtypes: The role of the underlying brain damage.
    Gois LCP; Pimentel-Silva LR; Damasceno BP; Damasceno A
    Mult Scler Relat Disord; 2021 Feb; 48():102701. PubMed ID: 33477004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
    Hechenberger S; Helmlinger B; Ropele S; Pirpamer L; Bachmaier G; Damulina A; Pichler A; Khalil M; Enzinger C; Pinter D
    Mult Scler Relat Disord; 2022 Jan; 57():103353. PubMed ID: 35158430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive trajectories in relapsing-remitting multiple sclerosis: Evidence of multiple evolutionary trends.
    London F; De Haan A; Benyahia Z; Landenne G; Duprez T; van Pesch V; El Sankari S
    Mult Scler Relat Disord; 2023 Sep; 77():104848. PubMed ID: 37390678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
    Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
    Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
    BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study.
    Kania K; Pawlak MA; Forycka M; Wiłkość-Dębczyńska M; Michalak S; Łukaszewska A; Wyciszkiewicz A; Wypych A; Serafin Z; Marcinkowska J; Kozubski W; Kalinowska-Łyszczarz A
    Neurol Neurochir Pol; 2024; 58(2):176-184. PubMed ID: 38324117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Neuropsychological Impairment in Relapsing Remitting Multiple Sclerosis: The Role of Clinical Measures, Treatment, and Neuropsychiatry Symptoms.
    Lozano-Soto E; Cruz-López ÁJ; Gutiérrez R; González M; Sanmartino F; Rashid-Lopez R; Espinosa-Rosso R; Forero L; González-Rosa JJ
    Arch Clin Neuropsychol; 2021 May; 36(4):475-484. PubMed ID: 33067616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis.
    Morelli ME; Baldini S; Sartori A; D'Acunto L; Dinoto A; Bosco A; Bratina A; Manganotti P
    Neurol Sci; 2020 Oct; 41(10):2893-2904. PubMed ID: 32333180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study.
    Heled E; Aloni R; Achiron A
    Appl Neuropsychol Adult; 2021; 28(2):210-219. PubMed ID: 31204507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcome measurements in a selective cohort of relapsing-remitting multiple sclerosis patients: relationships with physical disability, cognitive impairment, and MRI-derived metrics.
    London F; El Sankari S; De Haan A; Benyahia Z; Landenne G; Duprez T; van Pesch V
    Acta Neurol Belg; 2023 Jun; 123(3):1049-1059. PubMed ID: 36877357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    Wybrecht D; Reuter F; Pariollaud F; Zaaraoui W; Le Troter A; Rico A; Confort-Gouny S; Soulier E; Guye M; Maarouf A; Ranjeva JP; Pelletier J; Audoin B
    PLoS One; 2017; 12(11):e0184650. PubMed ID: 29149177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?
    Andravizou A; Siokas V; Artemiadis A; Bakirtzis C; Aloizou AM; Grigoriadis N; Kosmidis MH; Nasios G; Messinis L; Hadjigeorgiou G; Dardiotis E; Peristeri E
    Neurol Res; 2020 Jul; 42(7):575-586. PubMed ID: 32427076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
    Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
    J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.
    Bergendal G; Fredrikson S; Almkvist O
    Eur Neurol; 2007; 57(4):193-202. PubMed ID: 17272938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.